ImmunityBio (IBRX) Stock Overview
A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IBRX Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.67 |
| 52 Week High | US$12.43 |
| 52 Week Low | US$1.83 |
| Beta | -0.076 |
| 1 Month Change | -26.53% |
| 3 Month Change | 287.37% |
| 1 Year Change | 151.48% |
| 3 Year Change | 359.28% |
| 5 Year Change | -59.07% |
| Change since IPO | -80.18% |
Recent News & Updates
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
Mar 17Recent updates
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
Mar 17
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 07
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Apr 29ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Mar 07ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Jan 17ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Dec 11ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
Oct 25ImmunityBio: Moving The Needle
Oct 07ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Sep 21ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
Aug 14ImmunityBio: All Eyes On Execution Now (Rating Upgrade)
Jul 09ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Jun 25Shareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | 3.2% | -0.6% |
| 1Y | 151.5% | 31.7% | 16.0% |
Return vs Industry: IBRX exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: IBRX exceeded the US Market which returned 16% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 24.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBRX's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 688 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$7.87b |
| Earnings (TTM) | -US$351.40m |
| Revenue (TTM) | US$113.29m |
Is IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$113.29m |
| Cost of Revenue | US$753.00k |
| Gross Profit | US$112.54m |
| Other Expenses | US$463.93m |
| Earnings | -US$351.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 99.34% |
| Net Profit Margin | -310.18% |
| Debt/Equity Ratio | -160.8% |
How did IBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 01:33 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunityBio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |